• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.
By JAMES "REV SHARK" DEPORRE
Feb 07, 2018 | 10:53 AM EST
Stocks quotes in this article: CRSP, VKTX, GBT

Before, the open market indications were looking quite poor, but as soon as the opening bell rang, the buyers showed up. Breadth is solid, with about 4050 gainers to 2450, but there are only about 30 new 12-month highs after the deep dive earlier this week.

Since the carnage involving the volatility instruments, there has been a notable change in the level of liquidity. I'm not sure what the dynamic is that is causing this, but it is a major shift in the character of the action and suggests that volatility is going to pick up, like many pundits have been predicting lately.

The important thing for now is that the indices hold above the opening lows. If that level is tested, it is going to trigger some pressure on the indices. The confidence in the dip buyers has eroded, and the bears are likely to be increasingly bold should there be signs of a failed bounce.

The good news is that there are some pockets of speculative action. Biotechnology continues to offer some of the best movement, with names like CRISPR (CRSP) , Viking Therapeutics (VKTX) and Global Blood (GBT) acting well.

There is still some nervousness about chasing like many market players were doing two weeks ago, but I'm still optimistic that stock-picking is going to work well, as the market deals with the recent swings.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long VKTX, GBT, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare | Markets | How-to | Risk Management | Stocks

More from Healthcare

Boston Scientific Could Be Wicked Good in This Kind of Market

Brad Ginesin
May 24, 2022 2:13 PM EDT

Here's why this healthcare stock is a potential port in the storm for investors.

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login